4D Molecular Therapeutics, Inc. - 10-Q Filing
4D Molecular Therapeutics filed a 10-Q for the quarter ended March 31, 2026, disclosing financial and operational updates, including equity incentive plans, stock purchase agreements, and collaboration agreements, such as the Reignite Agreement and a collaboration with Otsuka Pharmaceutical Company Ltd.
Tickers: $FDMT